{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:13:55Z","timestamp":1722888835097},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T00:00:00Z","timestamp":1417564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00277-014-2246-2","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T12:53:31Z","timestamp":1417524811000},"page":"919-927","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A multi-state model approach for prediction in chronic myeloid leukaemia"],"prefix":"10.1007","volume":"94","author":[{"name":"German CML Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lauseker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,3]]},"reference":[{"issue":"11","key":"2246_CR1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004","journal-title":"N Engl J Med"},{"issue":"23","key":"2246_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"issue":"2","key":"2246_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B Methodol 34(2):187\u2013220","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"6","key":"2246_CR4","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/sim.2655","volume":"26","author":"M Pintilie","year":"2007","unstructured":"Pintilie M (2007) Analysing and interpreting competing risk data. Stat Med 26(6):1360\u20131367","journal-title":"Stat Med"},{"issue":"19","key":"2246_CR5","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1002\/sim.2823","volume":"26","author":"A Latouche","year":"2007","unstructured":"Latouche A, Beyersmann J, Fine JP (2007) Comments on \u2018Analysing and interpreting competing risk data\u2019 by M. Pintilie, Statistics in Medicine 2006. Stat Med 26(19):3676\u20133679. doi: 10.1002\/sim.2655","journal-title":"Stat Med"},{"issue":"3","key":"2246_CR6","first-page":"141","volume":"5","author":"OO Aalen","year":"1978","unstructured":"Aalen OO, Johansen S (1978) An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 5(3):141\u2013150","journal-title":"Scand J Stat"},{"issue":"6","key":"2246_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim D-W, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann J-L, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884","journal-title":"Blood"},{"issue":"12","key":"2246_CR8","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, M\u00fcller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, H\u00e4nel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Sau\u00dfele S (2011) Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634\u20131642","journal-title":"J Clin Oncol"},{"issue":"24","key":"2246_CR9","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1200\/JCO.2008.16.1000","volume":"26","author":"JR Anderson","year":"2008","unstructured":"Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26(24):3913\u20133915","journal-title":"J Clin Oncol"},{"issue":"11","key":"2246_CR10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"JR Anderson","year":"1983","unstructured":"Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11):710\u2013719","journal-title":"J Clin Oncol"},{"issue":"11","key":"2246_CR11","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26(11):2389\u20132430","journal-title":"Stat Med"},{"key":"2246_CR12","doi-asserted-by":"crossref","unstructured":"Pavlik T, Janousova E, Pospisil Z, Muzik J, Zackova D, Racil Z, Klamova H, Cetkovsky P, Trneny M, Mayer J, Dusek L (2011) Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. BMC Med Res Methodol 11:140. doi:10.1186\/1471-2288-11-140.).","DOI":"10.1186\/1471-2288-11-140"},{"issue":"21","key":"2246_CR13","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1002\/sim.3305","volume":"27","author":"M Fiocco","year":"2008","unstructured":"Fiocco M, Putter H, van Houwelingen HC (2008) Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models. Stat Med 27(21):4340\u20134358","journal-title":"Stat Med"},{"key":"2246_CR14","doi-asserted-by":"crossref","unstructured":"Touraine C, Helmer C, Joly P (2013) Predictions in an illness-death model. Stat Methods Med Res. [Epub ahead of print].","DOI":"10.1177\/0962280213489234"},{"issue":"3","key":"2246_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cmpb.2010.01.001","volume":"99","author":"LC Wreede de","year":"2010","unstructured":"de Wreede LC, Fiocco M, Putter H (2010) The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Prog Biomed 99(3):261\u2013274","journal-title":"Comput Methods Prog Biomed"},{"issue":"5","key":"2246_CR16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saussele S, Hochhaus A (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32(5):415\u2013423","journal-title":"J Clin Oncol"},{"issue":"3","key":"2246_CR17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.leukres.2007.03.031","volume":"32","author":"NC Cross","year":"2008","unstructured":"Cross NC, Hughes TP, Hochhaus A, Goldman JM (2008) International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 32(3):505\u2013506","journal-title":"Leuk Res"},{"issue":"11","key":"2246_CR18","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cross NCP, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23(11):1957\u20131963","journal-title":"Leukemia"},{"issue":"3","key":"2246_CR19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692","journal-title":"Blood"},{"issue":"2","key":"2246_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1191\/0962280202sm277ra","volume":"11","author":"JP Klein","year":"2002","unstructured":"Klein JP, Shu Y (2002) Multi-state models for bone marrow transplantation studies. Stat Methods Med Res 11(2):117\u2013139","journal-title":"Stat Methods Med Res"},{"issue":"12","key":"2246_CR21","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/sim.810","volume":"20","author":"N Keiding","year":"2001","unstructured":"Keiding N, Klein JP, Horowitz MM (2001) Multi-state models and outcome prediction in bone marrow transplantation. Stat Med 20(12):1871\u20131885","journal-title":"Stat Med"},{"key":"2246_CR22","doi-asserted-by":"crossref","unstructured":"Zeidner JF, Zahurak M, Rosner GL, Gocke CD, Jones RJ, Smith BD (2014) The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Leuk Lymphoma 1\u20137 [Epub ahead of print].","DOI":"10.3109\/10428194.2014.910868"},{"issue":"2","key":"2246_CR23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/cncr.25604","volume":"117","author":"A Al-Kali","year":"2010","unstructured":"Al-Kali A, Kantarjian H, Shan J, Bassett R, Quint\u00e1s-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O\u2019Brien S, Cortes J (2010) Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327\u2013335","journal-title":"Cancer"},{"issue":"6","key":"2246_CR24","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/(SICI)1097-0258(20000330)19:6<837::AID-SIM394>3.0.CO;2-3","volume":"19","author":"S Chevret","year":"2000","unstructured":"Chevret S, Leporrier M, Chastang C (2000) Measures of treatment effectiveness on tumour response and survival: a multi-state model approach. Stat Med 19(6):837\u2013848","journal-title":"Stat Med"},{"issue":"12","key":"2246_CR25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10654-005-3777-6","volume":"20","author":"R Cailliod","year":"2005","unstructured":"Cailliod R, Quantin C, Carli PM, Jooste V, Teuff GL, Binquet C, Maynadie M (2005) A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models. Eur J Epidemiol 20(12):993\u20131001","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"2246_CR26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3324\/haematol.2011.060087","volume":"97","author":"AL Petzer","year":"2012","unstructured":"Petzer AL, Dominic F, Thomas L, Irina D, Zvenyslava M, Andrija B, Laimonas G, Sandra L, Stefan G, Liana G, Aleksandar S, Dontcho P, Nikolay T, Rasa G, Atanas S, Thomas G, Marthin K, Peter S, Guenther G, Dominik W (2012) High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients\u2014final analysis of a randomized, multicenter, phase III trial. Haematologica 97(10):1562\u20131569","journal-title":"Haematologica"},{"issue":"8","key":"2246_CR27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.22076","volume":"86","author":"A Gafter-Gvili","year":"2011","unstructured":"Gafter-Gvili A, Leader A, Gurion R, Vidal L, Ram R, Shacham-Abulafia A, Ben-Bassat I, Lishner M, Shpilberg O, Raanani P (2011) High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients\u2014systematic review and meta-analysis. Am J Hematol 86(8):657\u2013662","journal-title":"Am J Hematol"},{"issue":"9134","key":"2246_CR28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352(9134):1087\u20131092","journal-title":"Lancet"},{"issue":"3","key":"2246_CR29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","volume":"23","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602\u2013604","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2246-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2246-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:16:33Z","timestamp":1717596993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2246-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,3]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2246-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2014,12,3]]}}}